-
J Clin Oncol: Clinical prognosis and molecular variation patterns after the recurrence of myeloma
Time of Update: 2021-02-01
study conducted clinical prognostic analysis of children and infants who experienced a recurrence of myeloma recruited in the SJMB03 (NCT0008520202) and SJYC07 (NCT00602667) trials, including the anatomy and time patterns of recurrence and survival after recurrence.
-
J Nucl Med: Safety and dose assessment of the treatment of osteosarcoma with the radioactive drug 177DOTA-ZOL
Time of Update: 2021-02-01
177Lu-DOTA-Cyric acid (177Lu-DOTA-ZOL) is a new radioactive drug for bone metastasis.
this is a forward-looking study in which researchers evaluated the safety and dosage of 177DOTA-ZOL at a single therapeutic dose based on a range of SPECT/CT images and blood samples.
-
Br J Cancer: ALG5: Biomarker candidate for malignant slurry ovarian cancer
Time of Update: 2021-02-01
136 late HGSOC cases with CGR were identified from three common transcription set data sets in patients with advanced HGSOC tumors and improved prognostication.
-
J Clin Oncol: The new PD-L1 inhibitor Toripalimab is safe and effective in treating chemotherapy refractory metastatic nasopharyngeal cancer
Time of Update: 2021-02-01
median tumor mutation load (TMB) in the prognostic (PFS and OS) queues of patients with different TMB states was 0.95 mut/megablyblyb, which had no predictive value for treatment response.
, polarIS-02 studies have shown that toripalimab has controlled safety and long-lasting clinical efficacy in patients with chemotherapy-resistant metastatic nasopharyngeal cancer.
-
J Clin Oncol: A risk model for predicting the toxicity of chemotherapy in older patients with early breast cancer
Time of Update: 2021-02-01
in summary, the Cancer and Aging Research Group -Breast Cancer (CARG-BC) score has been developed and has been validated to predict the risk of level 3-5 chemotherapy toxicity during chemotherapy in older patients with early breast cancer.
-
Br J Cancer: Risk analysis of subsequent cancer occurrence in retinal scleoma survivors
Time of Update: 2021-02-01
in this study, the researchers quantified the risk of SMN events in 1,128 genetic and 924 non-hereditary retinal cell tumor survivors through long-term follow-up and detailed histological information (diagnosed between 1914 and 2006; follow-up through 2016).
-
Br J Cancer: EEF1A2 mediates the epitheline-interstital transformation process to promote the metastasis of pulmonary adenocarcinoma
Time of Update: 2021-02-01
Although previous studies have revealed the expression characteristics of targeted KRAS and EGFR mutations and EML4-ALK fusion genes in LUAD and developed appropriate treatment strategies, the total five-year survival rate for lung adenocarcinoma patients is still very low, at only 18%.
-
J Clin Oncol: Clinical calculators based on molecular and clinical pathological characteristics predict the risk of recurrence after stage I-III colon cancer
Time of Update: 2021-02-01
The clinical calculator consists of six variables: microsatellite genomic esology, AJCC T classification, number of tumor-tired lymph nodes, presence of high-risk pathological characteristics (e.g. intravenous, lymphatic tube or nerve immersion), presence of tumor-incussive lymphocytes, and use of complementary chemotherapy.
-
Clin Cancer Res: The number of circulating tumor cell subtypes and T cells predicts the prognosticity of patients with metastatic genitourinary tract cancer
Time of Update: 2021-01-31
study compared the CTC characteristics and the relationship between T-cell count and end-of-life in a group of patients with metastatic genitourinary tract (mGU) cancer who received combined immunotherapy.
-
Ann Surg: Preoperative exercise rehabilitation exercise can reduce the risk of complications after rectal excision in high-risk elderly patients
Time of Update: 2021-01-31
study aims to assess the effect of a three-week community exercise program on the incidence of complications 30 days after surgery in high-risk patients with a malignant tumor or precancerog lesions.
, preoperative exercise rehabilitation can reduce the risk of postoperative complications in high-risk patients receiving a selected colonectomy.
-
Diagnosis and treatment of neuroendocrine tumors in the cervix
Time of Update: 2021-01-31
In a pathology report that included 24 cases of neuroendocrine cervical cancer in large and small cells in patients, MD Anderson Cancer Center studied immunoglobic expression and prognosis of HER-2/neu, skin growth factor receptors (EGFR), endodertic growth factors (VEGF), epoxyase-2 (COX-2), estrogen receptors, and progesterone receptors.
-
Not CAR-T / NK / M, new cell therapy technology is coming, the goal is to conquer solid tumors!
Time of Update: 2021-01-31
January 6, his new company, Myeloid Therapeutics, launched for more than $50 million, with Newpath Partners, 8VC and others to launch clinical trials on T-cell lymphoma, glioblastoma and other solid tumors, as well as further development of myeloid therapy.
-
Cell Death Differ: Single-cell RNA sequencing reveals heterogeneity in tumors of primary grape membrane melanoma
Time of Update: 2021-01-31
Single-celled RNA-seq revealed a poor prognosis of cell subgroups In this study used multiple-scale analysis using single-cell RNA sequencing of six different primary grape membrane melanomas, the researchers found heterogeneity in tumors at the genomic and transcriptional group levels.
-
Japanese musician Sakamoto has been diagnosed with rectal cancer! Eighty percent of patients have been diagnosed with colorectal cancer in the middle and late stages
Time of Update: 2021-01-31
Dietary fiber is not digested in the intestine, can stimulate gastrointestinal peristalsis, speed up the transport of intestinal contents, soften feces, increase fecal volume, adsorption of carcinogens, thereby reducing the carcinogen's action on the intestinal mucous membrane concentration and contact time, which is an important reason why it can help us prevent colorectal cancer.
-
Nat Commun: Let macrophages carry metformin, enhancing PD-1 anti-tumor effect
Time of Update: 2021-01-31
January 19, 2021, a team of Professors Yang Xiangliang, Professor Gan Wei and Huang Bo of the Chinese Academy of Medical Sciences published a research paper online in the journal Nature Communications entitled Boosting Anti-PD-1 Therapy with Metformin-Loaded Macrophage-Derived Microparticles.
-
J Clin Oncol: Beval monoantigens and carptonins and yew alcohols can significantly improve the prognosis of metastasis mucosal melanoma
Time of Update: 2021-01-31
the study is an open-label, randomized Phase II trial designed to assess the efficacy and safety of beval's monoantigenated carbide and yew alcohol (CPB) for previously treated late-stage MMs.
the objective mitigation rates of the CCP group and the CP group were 19.7% and 13.2%, respectively.
-
Second-generation broad-spectrum anti-cancer TRK inhibitors may solve the problem of ententinib or larotinib resistance
Time of Update: 2021-01-31
Figure 2.1 Drug resistance and off-target information for 1st generation TRK inhibitors (Image source: s41571-018-0113-0) Non-target resistance is similar to ARK and ROS1 fusion-positive lung cancer, which can develop non-target resistance to tyrosine kinase inhibitor therapy.
-
Lancet Gastroen Hepatol: Short-term radiotherapy combined with endoscopic microscopic surgery to treat early rectal cancer
Time of Update: 2021-01-31
study concluded that for patients with early rectal cancer, short-term radiotherapy after endoscopic microscopic surgery in disease control is comparable to the whole rectal membrane excision, but in patients with improved quality of life is better than the whole rectal membrane excision.
-
Guide Express || 2020 ESGO/SIOPE Guide: Management of Non-Cortized Ovarian Cancer in Adolescents and Young People
Time of Update: 2021-01-31
√ According to the final pathology report, if the initial surgical cyst excision/tumor excision, there are no signs of ancillary treatment, and the serum tumor markers are normal, secondary surgery is required to remove the remaining ovaries to reduce the risk of recurrence.
-
Br J Cancer: Retrospective queue study for Vismodegib treatment of patients with advanced and multiple substrate cell carcinoma
Time of Update: 2021-01-31
the study aims to assess the efficacy of vismodegib in treating patients with laBCC, mBCC, and substrate cellular syndrome (BCNS), as well as tumor characteristics that are more likely to be fully mitigated.
